# Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

> **NCT06040086** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 1454 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Placebo
- **DRUG:** Tozorakimab

## Key facts

- **NCT ID:** NCT06040086
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-22
- **Primary completion:** 2026-03-06
- **Final completion:** 2026-05-22
- **Target enrollment:** 1454 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06040086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06040086, "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06040086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*